Epidemiological profiles of viral hepatitis in Italy Effects of migration

Similar documents
Hepatitis E Virus Infection. Disclosures

Hepatitis E in South Africa. Tongai Maponga

Viral Hepatitis in Reproductive Health

Hepatitis E FAQs for Health Professionals

Hepatitis A-E Viruses. Dr Nemes Zsuzsanna

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Hepatitis E in developing countries

Hepatitis A and Hepatitis E

Epidemiology of hepatitis B and D in Greece

HAV HBV HCV HDV HEV HGV

Summary of Key Points WHO Position Paper on Vaccines against Hepatitis E Virus(HEV) May 2015

Emerging TTIs How Singapore secure its blood supply

Update of hepa++s E in Hong Kong. Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital

Viral Hepatitis. Viral Hepatitis. Infectious Disease Epidemiology BMTRY 713 Viral Hepatitis. March 23, Selassie AW (DPHS, MUSC) 1

Transmission of HEV by plasmapheresis. Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm

Viral Hepatitis in Ireland, 2005

Viral Hepatitis Diagnosis and Management

Hepatitis A Surveillance Protocol

EPIDEMIOLOGY OF HEPATITIS A IN IRELAND

Viral Hepatitis. Background

Viral Hepatitis - Historical Perspective

Test Name Results Units Bio. Ref. Interval

Hepatitis A Case Investigation and Outbreak Response. Terrie Whitfield LPN Public Health Representative

HEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)

Epidemiology of HAV, HDV and HEV in Belgium

We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

E E Hepatitis E SARS 29, Lancet. E A B Enterically-Transmitted Non-A, Hepatitis E. Virus HEV nm. 1.35g/cm s ALT AST HEV HEV

Hepatitis E in humans. Alfredo Pérez (Hospital 12 de Octubre, Madrid. Spain)

HEPATITIS E. Enterically transmitted zoonotic RNA virus in the genus Hepevirus 7200 bases 3 ORFs

Notes Setting the Scene

Erratum to: A systematic review of the epidemiology of hepatitis E virus in Africa

Hepatitis E Virus Update December 2014

Hepa%%s E Virus Is it a Concern?

EAST LONDON INTEGRATED CARE

Epidemiology of hepatitis E infection in Hong Kong

Chapter 2 Hepatitis B Overview

Epidemiology Update Hepatitis A

CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE

Rama Nada. - Malik

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

Media centre. WHO Hepatitis B. Key facts. 1 of :12 AM.

Hepatitis B infection

Hepatitis A Virus: Old Things Made New

Is it the time to start blood screening for Hepatitis-E?

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

Hepatitis Serology and Background Notes

Series of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)

Epidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

Test Name Results Units Bio. Ref. Interval

Groups at risk for hepatitis B infection - who should be vaccinated

HEPATITIS A. Figure 35. Figure 36. Hepatitis A Incidence Rates by Year LAC and US,

Confirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).

Hepatitis C Best Practice Guidelines For Local Health Departments

Seroprevalence of Hepatitis B Surface Antigen (HBsAg) Among Patients at a Tertiary Care Hospital in Mumbai, India

keyword: hepatitis Hepatitis

Viral Hepatitis in Children DR. HOSSAIN IBRAHIM AGEEL PEDIATRIC GASTROENTEROLOGIST PEDIATRIC DEPARTMENT KFCH JAZAN

Kalliopi Azariadi, Pinelopi Arvaniti, Nikolaos Gatselis, George N. Dalekos, Kalliopi Zachou

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003

HBV : Structure. HBx protein Transcription activator

New recommendations for immunocompromised patients

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature

Hepatitis A Virus Infections

Hepatitis. Epidemiology and Prevention of Viral Hepatitis A, B, and C:

Hepatitis A Outbreaks In Australia Molecular Epidemiology

HEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011

Epidemiology of hepatitis A and E in Greece. V. Papaevangelou

Objectives. Acute Hepatitis: Symptoms. Acute Hepatitis: Signs HIHIM 409. Acute Viral Hepatitis by Type, United States,

Hepatitis E and the English blood supply

Viral Hepatitis, 2004

Hepatitis Case Investigation

Research article Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data

Some HCV History 1970s: many cases reported called non-a, non-b hepatitis

Epidemiology of HCV infection among HD pts in Iran and prevention strategies

Test Name Results Units Bio. Ref. Interval

Detection of HEV in Estonia. Anna Ivanova, Irina Golovljova, Valentina Tefanova

Hepatitis E virus in Israel

Hepatitis B and Hepatitis B Vaccine

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Healthy Liver Cirrhosis

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Detection of IgA-class anti-hev antibody

Hepatitis A is a small, unenveloped, symmetrical RNA virus within the genus Hepatovirus, a member of the Picornavirus family.

Lifetime risk of infection >60% Early childhood infections common

DISCLOSURES RELEVANT TO THIS PRESENTATION NONE. Off label use of drugs will be discussed

Viral Hepatitis in the WHO South-East Asia Region

La storia clinica del paziente con infezione cronica da HCV: focus epidemiologico. Monica Schiavini

Health Care Workers and Viral Hepatitis in Turkey. Bulent Degertekin M.D. Viral Hepatitis Prevention Board Meeting

MI Flu Focus. Influenza Surveillance Updates Bureaus of Epidemiology and Laboratories

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

Hepatitis E Seroconversion. Following plasma exchange

The ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board

Transcription:

Epidemiological profiles of viral hepatitis in Italy Effects of migration Hepatitis A and E T. Santantonio UOC di Malattie Infettive Università degli Studi di Foggia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Foggia

Enterically transmitted A E Viral Hepatitis Parenterally transmitted B C D

HEPATITIS A VIRUS non-enveloped virus particle (Ø 28 nm) positive sense, single-stranded RNA virus ~ 7.5 Kb in length 6 genotypes, one serotype Family: Picornaviridae (genus Hepatovirus)

Hepatitis A: clinical features Severity Variable and age-dependent Most childhood infections are asymptomatic (>90% <5 years) 70-90% infected adults develop symptomatic disease Cholestatic hepatitis, relapsing hepatitis, fulminant hepatitis Mortality Age-dependent (0.6-2.1%) Chronic Carrier state No chronic infection

Geographic distribution of HAV infection Anti-HAV prevalence: high high/intermediate intermediate low very low Data from CDC, USA

Endemicity and seroprevalence Seroprevalence (%) 100 80 60 40 20 0 <5 5 10 10 15 15 20 20 25 25 30 35 40 40 45 45 50 >50 Age group high intermediate low Adapted from: Luxemburger C. J Travel Med 2005; 12 S12-S21

Evolving epidemiology of hepatitis A in Italy Annual incidence has progressively declined in recent decades due to: Social, behavioural and demographic changes Improvements in the standard of living and hygiene Presence of clean water and proper sewage disposal Vaccination

The shift in Hepatitis A prevalence in Italy 100 75 1970s 1990s % anti-hav 50 25 0 0 10 20 30 40 50 60 >60 age

Prevalence of anti-hav in Italian recruits (18-26 years) % 100 83.3 64.3 North-Center South-Islands 50 0 45.2 27.3 22.4 32.2 5.3 2.1 1981 1990 2003 7.9 D Amelio et al, Emerg Infected Dis 2005;11:1155-6

Tassi di incidenza (x 100.000) dell'epatite A per età ed anno di notifica. SEIEVA 1985-2010.

Hepatitis A outbreaks in Puglia 160 140 11.000 cases Cases per 100.000 120 100 80 60 40 3000 cases 1400 cases 20 0 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 P Lopalco et al, Eurosurveillance 1997; 2:31-2

Acute Hepatitis A: Time-trend of reported risk factors % 100 90 80 70 60 50 40 30 20 10 Contact with a jaundice case Shellfish consumption Travel Children day care IVDU 0 1991 1993 1995 1997 1999 2001 2003 2005 SEIEVA 1991-2006

Hepatitis A vaccination Schedule: 0, 6 mos or 0-12 mos or 0-18 mos Excellent immunogenicity and safety Efficacy in outbreak control and post-exposure prophylaxis * Co-administration with Ig or other vaccines (HB) is possible * Sagliocca et al, Lancet 1999; Webster et al, BMJ 2001

HAV vaccination recommendations Travellers to high endemic areas Military personnel travelling to high endemic areas Sewage workers Individuals with blood-clotting disorders Intravenous drug addicts Homosexual men Prisoners Patient with chronic liver disease and/or cirrhosis

Regional recommendation for HAV vaccination Due to the periodical occurrence of large outbreaks in Puglia, vaccination against hepatitis A has been implemented for children at: - 16-18 months of age - 12 years of age This strategy aims to reduce the incidence of new infections and prevent infection in adulthood, when the clinical consequences of disease are more severe

Hepatitis A and migration Anti-HAV prevalence: high high/intermediate intermediate low very low Data from CDC, USA

Anti-HAV prevalence in immigrants Author Santantonio et al Eur J Epidemiol 1993 Chironna et al Int J Infect Dis 2001 Chironna et al Infection 2003 Maiori et al J Travel Med 2008 Subjects Country of origin Anti-HAV Ig-G Anti-HAV IgM 393 Albania 96% nt 526 Kosovo 81% nt 1005 Iraq and Turkey 94.4% nt 182 Sub-Saharian Africa 99.5% 0

Hepatitis A and migration High prevalence of HAV antibodies in immigrants from areas with high/intermediate endemicity Unlikely impact of migration on epidemiological status of hepatitis A in Italy

HEPATITIS E VIRUS 1980: recognized as a new virus 1983: identified by IEM 1990: cloned, sequenced, and named hepatitis E virus non-enveloped virus particle (Ø 27-34 nm) + sense, single-stranded RNA virus ~ 7.2 Kb in length Family: Hepeviridae (genus Hepevirus) Hepeviridae

HEV: a single serotype, 4 major genotypes genotype 4 genotype 4 genotype 3 genotype 3 genotype 2 genotype 2 genotype 1 genotype 1 Aggarwal and Naik, J Gastroenterol Hepatol 2009; 24:1484-93

World map showing regions where hepatitis E is highly endemic

Geographic distribution of HEV genotypes Human HEV Swine HEV Purcell and Emerson. J Hepatol 2008; 48:494-503

Differences in epidemiological and clinical features associated with hepatitis E in disease-endemic and non-endemic regions Feature Endemic regions Non-endemic regions Geographical locations Asia and Africa Developed countries Epidemiological patterns Epidemics, sporadic cases Only sporadic cases Water-borne transmission Most common route Unknown Zoonotic transmission Not reported Shown, a common mode of transmission Animal reservoir No Yes Virus genotype G1 and G2, G4 in China G3 Age group Young adults Usually elderly Chronic infection Not known Transplant recipients receiving immunosuppressive drugs Severity Variable, including FH Severity related to coexistent diseases Relationship with pregnancy High rate of symptomatic disease and FH No data Aggarwal and Naik, J Gastroenterol Hepatol 2009; 24:1484-93

Prevalence of anti-hev IgG Average: 6.5% 7.2 % 16% 6.1% ~2% 3.2% 14% USA: 21% Kuniholm et al J Infect Dis 2009;200:48-56 16.6% 7.3% 1-6% 8.4% Viral Hepatitis Prevention Board, 2009

Anti-HEV prevalence in Italian population and in immigrants in Foggia province 1217 subjects Italian population = 805 151 blood donors 450 healthy individuals 100 HIV-positive patients 104 hemodialysis patients Immigrants = 412 Africa: 286 Asia: 86 East Europe:40 IgG anti-hev (EIA, Western Blot), IgM anti-hev Scotto et al, EASL 2011

Anti-HEV prevalence in Foggia % 25 20 15 10 - Anti-HEV IgG positive= 107/1217 (8.8%) - Anti-HEV IgM positive= 20/107 (18.7%), 17 immigrants, 3 Italians -ALT = 8/20 8.6 8,6 19,7 19.7 5 0 hemodialysis patients 2 2.0 0,7 0.7 3.1 3,1 HIV positive blood donors healthy subjects immigrants Scotto et al, EASL 2011

Anti-HEV prevalence in immigrants n. subjects anti-hev positive 60 50 40 30 20 10 0 51 21 9 Sub-Saharan Africa Asia East Europe N. 286 86 40 Scotto et al, EASL 2011

Anti-HEV prevalence in Lecce province Anti-HEV IgG (EIA, Western Blot) 15.3 % 2.9 0.7 4.3 n. 820 142 211 98 De Donno et al., Ann Ig 2003; 15(3). 199-205

Anti-HAV and anti-hev prevalence rates in Kurd refugees from Iraq and Turkey % 100 90 80 70 60 50 40 30 20 10 0 94.4 94,4 Anti-HEV IgG (EIA, Western Blot) 1,005 subjects 14.8 17.5 14,8 17,5 anti HAV anti HEV anti HEV Iraq immigrants 10.0 anti HEV Turkey immigrants Chironna M et al, Infection 2003; 31(2):69

Hepatitis E in Italy: a long-term prospective study Study population: 651 patients with acute nanc hepatitis Period: 1994-2009 Case definition: IgM anti-hev and/or HEV RNA positive in sera/stools by nested RT-PCR (ORF1 and ORF2) Romanò et al, J Hepatol 2011; 54:34-40

Laboratory diagnosis of hepatitis E 651 651 patients with with acute non non A nonc hepatitis 134 (20.6%) anti-hev IgM IgM and and IgG IgG positive 39 39 (6%) anti-hev IgG IgG positive 478 (73.4%) HEV HEV negative 96 96 (71.6%) HEV HEV RNA RNA positive in in sera sera Romanò et al, J Hepatol 2011; 54:34-40

Risk factors associated to hepatitis E Autochthonous 16.4% (22/134) Travel abroad 81.3% (109/134) 98 immigrants 11 Italians 2 Morocco 1 Somalia 1 Angola 1 Sri Lanka 1 CapeVerde 1 Somalia 22 Pakistan 43 Bangladesh 38 India Secondary cases 2.3% (3/134) 0 5 10 15 20 25 30 35 40 45 0 5 10 15 20 25 30 35 40 45 N of cases Romanò et al, J Hepatol 2011; 54:34-40

Hepatitis E in Italy: clinical features Self-limited disease with normalization of ALT within 3-6 weeks Mean duration of HEV RNA was 10 days in sera and 15 days in stools IgM anti-hev tended to disappear in 3-4 weeks, while IgG anti-hev continued to be detected throughout follow-up (up to 2.5 yrs) Romanò et al, J Hepatol 2011; 54:34-40

Sequencing and phylogenetic analysis Romanò et al, J Hepatol 2011; 54:34-40

Hepatitis E virus in Italy: molecular analysis of travel-related and autochthonous cases 17 patients with acute hepatitis E (anti-hev IgG and/or IgM, HEV RNA positive (ORF1, ORF2) infection No. HEV genotype Travel-related 12 G1 Autochthonous 5 G3 La Rosa et al, J Gen Virol 2011; 92:1617-1626

Molecular detection of HEV in sewage samples Molecular screening of raw sewage samples from 11 wastewater treatment plants in different regions of Italy 19/118 samples (16%) positive for HEV RNA in 9 of 11 regions analyzed 18 isolates 1 isolate G1 strains G3 strain La Rosa et al, Applied and Environmental Microbiology 2010; 76: 5870-73

Hepatitis E and migration The increasing number of people travelling to exotic countries plus the migratory flux of people from HEV endemic areas might alter the epidemiological picture of hepatitis E in Italy Epidemiological and molecular-epidemiological surveillance projects are necessary to: - establish prevalence - trace patterns of spread - guide prevention strategies